Mangalam Drugs & Organics (BOM:532637) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532637 Mangalam Drugs & Organics Ltd BOM:532637
43 GF Score
Price ₹31.67
GF Value ₹62.68
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics SpecialCharges?

Special Charges only applies to banks.

BOM:532637
43GF Score
Mangalam Drugs & Organics Ltd BOM:532637
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mangalam Drugs & Organics (BOM:532637) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹31.67 is trading 49.5% below its estimated GF Value™ of ₹62.68. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for BOM:532637:

  • SpecialCharges:
  • GF Value™: ₹62.68 vs. price of ₹31.67 (49.5% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the BOM:532637 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mangalam Drugs & Organics Business Description

Other Exchanges MANGALAM:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score

Get the complete analysis for BOM:532637

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.67
Price
₹62.68
GF Value